Literature DB >> 11134514

A mouse model of familial porphyria cutanea tarda.

J D Phillips1, L K Jackson, M Bunting, M R Franklin, K R Thomas, J E Levy, N C Andrews, J P Kushner.   

Abstract

Approximately one-third of patients with porphyria cutanea tarda (PCT), the most common porphyria in humans, inherit a single mutant allele of the uroporphyrinogen decarboxylase (URO-D) gene. PCT associated with URO-D mutations is designated familial PCT. The phenotype is characterized by a photosensitive dermatosis with hepatic accumulation and urinary excretion of uroporphyrin and hepta-carboxylic porphyrins. Most heterozygotes for URO-D mutations do not express a porphyric phenotype unless hepatic siderosis is present. Hemochromatosis gene (HFE) mutations are frequently found when the phenotype is expressed. We used homologous recombination to disrupt one allele of murine URO-D. URO-D(+/-) mice had half-wild type (wt) URO-D protein and enzymatic activity in all tissues but did not accumulate hepatic porphyrins, indicating that half-normal URO-D activity is not rate limiting. When URO-D(+/-) mice were injected with iron-dextran and given drinking water containing delta-aminolevulinic acid for 21 days, hepatic porphyrins accumulated, and hepatic URO-D activity was reduced to 20% of wt. We bred mice homozygous for an HFE gene disruption (HFE(-/-)) to URO-D(+/-) mice, generating mice with the URO-D(+/-)/HFE(-/-) genotype. These animals developed a porphyric phenotype by 14 weeks of age without ALA supplementation, and URO-D activity was reduced to 14% of wt. These data indicate that iron overload alone is sufficient to reduce URO-D activity to rate-limiting levels in URO-D(+/-) mice. The URO-D(+/-) mouse serves as an excellent model of familial PCT and affords the opportunity to define the mechanism by which iron influences URO-D activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134514      PMCID: PMC14578          DOI: 10.1073/pnas.98.1.259

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Cutaneous porphyria in Turkey.

Authors:  R SCHMID
Journal:  N Engl J Med       Date:  1960-08-25       Impact factor: 91.245

2.  Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells.

Authors:  K R Thomas; M R Capecchi
Journal:  Cell       Date:  1987-11-06       Impact factor: 41.582

3.  Molecular cloning and nucleotide sequence of a complete human uroporphyrinogen decarboxylase cDNA.

Authors:  P H Roméo; N Raich; A Dubart; D Beaupain; M Pryor; J Kushner; M Cohen-Solal; M Goossens
Journal:  J Biol Chem       Date:  1986-07-25       Impact factor: 5.157

4.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Macrocyclic intermediates in the biosynthesis of porphyrins.

Authors:  A H Jackson; H A Sancovich; A M Ferramola; N Evans; D E Games; S A Matlin; G H Elder; S G Smith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1976-02-05       Impact factor: 6.237

6.  Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes.

Authors:  S L Mansour; K R Thomas; M R Capecchi
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

7.  Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III.

Authors:  H de Verneuil; S Sassa; A Kappas
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

8.  Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda.

Authors:  G H Elder; A J Urquhart; R E De Salamanca; J J Munoz; H L Bonkovsky
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

9.  Isolation and identification of a cDNA clone coding for rat uroporphyrinogen decarboxylase.

Authors:  P H Romeo; A Dubart; B Grandchamp; H de Verneuil; J Rosa; Y Nordmann; M Goossens
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Uroporphyrinogen decarboxylase structural mutant (Gly281----Glu) in a case of porphyria.

Authors:  H de Verneuil; B Grandchamp; C Beaumont; C Picat; Y Nordmann
Journal:  Science       Date:  1986-11-07       Impact factor: 47.728

View more
  20 in total

1.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

2.  Uroporphyria in the Cyp1a2-/- mouse.

Authors:  John D Phillips; James P Kushner; Hector A Bergonia; Michael R Franklin
Journal:  Blood Cells Mol Dis       Date:  2011-08-30       Impact factor: 3.039

Review 3.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

Review 4.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

5.  Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria.

Authors:  Marie-Berengere Troadec; David Warner; Jared Wallace; Kirk Thomas; Gerald J Spangrude; John Phillips; Oleh Khalimonchuk; Barry H Paw; Diane McVey Ward; Jerry Kaplan
Journal:  Blood       Date:  2011-02-10       Impact factor: 22.113

6.  Mass-spectrometric profiling of porphyrins in complex biological samples with fundamental, toxicological, and pharmacological applications.

Authors:  Sarah A Sullivan; Bennett R Streit; Ethan L Ferguson; Paul A Jean; Debra A McNett; Louis T Llames; Jennifer L DuBois
Journal:  Anal Biochem       Date:  2015-03-10       Impact factor: 3.365

7.  Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.

Authors:  David F Bishop; Annika Johansson; Robert Phelps; Amr A Shady; Maria C M Ramirez; Makiko Yasuda; Andres Caro; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-02-09       Impact factor: 11.025

Review 8.  [Porphyria cutanea tara].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

9.  Structural basis for tetrapyrrole coordination by uroporphyrinogen decarboxylase.

Authors:  John D Phillips; Frank G Whitby; James P Kushner; Christopher P Hill
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

10.  A mouse chromosome 4 balancer ENU-mutagenesis screen isolates eleven lethal lines.

Authors:  Melissa K Boles; Bonney M Wilkinson; Andrea Maxwell; Lihua Lai; Alea A Mills; Ichiko Nishijima; Andrew P Salinger; Ivan Moskowitz; Karen K Hirschi; Bin Liu; Allan Bradley; Monica J Justice
Journal:  BMC Genet       Date:  2009-03-06       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.